A prospective study, a randomized clinical trial, carried out in patients with HIV/AIDS and with outpatient follow-up at a specialized unit in the city of Cuiabá-MT. Keyword: Glutamine, Immune System, HIV e HIV Long-Term Survivors.
Conditions
Interventions
Patients belonging to group A (n=10) received L-glutamine (0.5 mg / kg / day - maximum dose 30 g) and those in group B, maltodextrin 12% (0.5 mg / kg / day - maximum dose 30 g) . Both products were pa
b) metabolic evaluation by means of the following dosages: complete blood count, complete lipidogram, glycemia and basal insulin, liver function tests (transaminases, total protein and fraction, total
Dietary supplement
SP6.051.227
Sponsors
Universidade Federal de Mato Grosso
Universidade Federal de Mato Grosso
Eligibility
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: The study included patients considered to be adherent to the treatment, both men and women, between 18 and 50 years of age with positive serology for HIV/AIDS, enrolled in this unit, in regular treatment / follow-up and in the use of antiretroviral drugs (zidovudine / lamivudine and lopinavir / ritonavir) for at least two years, with Global Subjective Assessment = A (well nourished), who accepted to participate in the research with prior signature of the Informed Consent Term (TCLE)
Exclusion criteria
Exclusion criteria: Exclusion criterion were: patients who started treatment less than 2 years ago; with comorbidities; with a history of gastrointestinal tract operations; who used drugs that induced metabolic changes, as well as drug addicts and alcoholics. Also excluded were clinically severe or unstable patients, in addition to pregnant or infants; people with some mental disorder; who used glutamine or other supplement; patients with Global Subjective Evaluation B or C (moderately undernourished or severely undernourished) and patients who did not agree to participate in the study or did not sign the consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Significant statistical difference was observed in the basal insulin dosage in the A/L-glutamine group between the first and eighth day of supplementation, given not identified in group B maltodextrin (7.1 ± 2.7 vs. 4.8 ± 2.0; p=0.023). Other variables did not present significant statistical difference.;The demographic data evaluated were similar between the two groups. All patients were classified as well nourished (ASG A) according to the Global Subjective Assessment. Identical mean weight in both groups (p=0.093). For measurements of CD4 + (p=0.832) and CD8 + (p=0.974), both groups did not present statistical significance. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are not expected | — |
Countries
Brazil
Contacts
Public ContactCamila Ribas
Universidade Federal de Mato Grosso
Outcome results
None listed